SEARCH

SEARCH BY CITATION

References

  • Ballantyne C. M., Herd J. A., Dunn J. K., Jones P. H., Farmer J. A. & Gotto A. M. Jr (1997) Effects of lipid lowering therapy on the progression of coronary and carotid artery disease. Curr. Opin. Lipidol. 8, 354361.
  • Behl C. (1997) Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res. 290, 471480.DOI: 10.1007/s004410050955
  • Borchelt D. R., Thinakaran G., Eckman C. B., Lee M. K., Davenport F., Ratovitsky T., Prada C. M., Kim G., Seekins S., Yager D., Slunt H. H., Wang R., Seeger M., Levey A. I., Gandy S. E., Copeland N. G., Jenkins N. A., Price D. L., Younkin S. G. & Sisodia S. S. (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1–42/1–40 ratio in vitro and in vivo. Neuron 17, 10051013.
  • Citron M., Diehl T. S., Capell A., Haass C., Teplow D. B. & Selkoe D. J. (1996) Inhibition of amyloid beta-protein production in neural cells by the serine protease inhibitor AEBSF. Neuron 17, 171179.
  • Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A. Y., Seubert P., Vigo-Pelfrey C., Lieberburg I. & Selkoe D. J. (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360, 672674.
  • De Strooper B., Annaert W., Cupers P., Saftig R., Craessaerts K., Mumm J. S., Schroeter E. H., Schrijvers V., Wolfe M. S., Ray W. L., Goate A. & Kopan R. (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518522.
  • Dovey H. R., Suomensaari-Chrysler S., Lieberburg L., Sinha S. & Keim P. S. (1993) Cells with a familial Alzheimer's disease mutation produce authentic beta-peptide. Neuroreport 4, 10391042.
  • Esch F. S., Keim P. S., Beattie E. C., Blacher R. W., Culwell A. R., Oltersdorf T., McClure D. & Ward P. J. (1990) Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248, 11221124.
  • Figueiredo-Pereira M. E., Efthimiopoulos S., Tezapsidis N., Buku A., Ghiso J., Mehta P. & Robakis N. K. (1999) Distinct secretases, a cysteine protease and a serine protease, generate the C termini of amyloid beta-proteins Abeta1–40 and Abeta1–42, respectively. J. Neurochem. 72, 14171422.
  • Frautschy S. A., Yang R., Irrizarry M., Hyman B., Saido T. C., Hsiao K. & Cole G. M. (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol 152, 307317.
  • Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens L., Donaldson T., Gillespie E. & Et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523527.
  • Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B. & Et al. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322325.
  • Hardy J. (1996) New insights into the genetics of Alzheimer's disease. Ann. Med. 28, 255258.
  • Higaki L., Quon D., Zhong Z. & Cordell B. (1995) Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 14, 651659.
  • Hsiao K., Chapman R., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang R. & Cole G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99102.DOI: 10.1126/science.274.5284.99
  • Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., Lieberburg I., Schenk D., Seubert P. & McConlogue L. (1997) Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl Acad. Sci. USA 94, 15501555.DOI: 10.1073/pnas.94.4.1550
  • Klafki H. W., Paganetti P. A., Sommer B. & Staufenbiel M. (1995) Calpain inhibitor I decreases beta A4 secretion from human embryonal kidney cells expressing beta-amyloid precursor protein carrying the APP670/671 double mutation. Neurosci. Lett. 201, 2932.DOI: 10.1016/0304-3940(95)12122-k
  • Masliah E., Sisk A., Mallory M., Mucke L., Schenk D. & Games D. (1996) Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J. Neurosci 16, 57955811.
  • Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I. & Rydel R. E. (1992) beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376389.
  • Mattson M. P., Partin J. & Begley J. G. (1998) Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res. 807, 167176.DOI: 10.1016/s0006-8993(98)00763-x
  • Mayeux R., Tang M. X., Jacobs D. M., Manly L., Bell K., Merchant C., Small S. A., Stern Y., Wisniewski H. M. & Mehta P. D. (1999) Plasma amyloid beta-peptide 1–42 and incipient Alzheimer's disease. Ann. Neurol. 46, 412416.
  • Oltersdorf T., Ward P. L., Henriksson T., Beattie E. C., Neve R., Lieberburg I. & Fritz L. C. (1990) The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. J. Biol. Chemistry 265, 44924497.
  • Savage M. L., Trusko S. P., Howland D. S., Pinsker L. R., Mistretta S., Reaume A. G., Greenberg B. D., Siman R. & Scott R. W. (1998Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J. Neurosci 18, 17431752.
  • Schenk D. B., Rydel R. E., May P., Little S., Panetta J, Lieberburg I. & Sinha S. (1995) Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease. J. Med. Chem. 38, 41414154.
  • Selkoe D. J. (1994) Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53, 438447.
  • Selkoe D. L., Yamazaki T., Citron M., Podlisny M. B., Koo E. H., Teplow D. B. & Haass C. (1996) The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann. NY Acad. Sci. 777, 5764.
  • Seubert P., Oltersdorf T., Lee M. G., Barbour R., Blomquist C., Davis D. L., Bryant K., Fritz L. C., Galasko D. & Thal L. J. et al. (1993) Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 361, 260263.
  • Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J. & Swindlehurst C. et al. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325327.
  • Sinha S., Anderson J. P., Barbour R., Basi G. S., Caccavello R., Davis D., Doan M., Dovey H. F., Frigon N. & Hong L. et al. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537540.
  • Steiner H., Duff K., Capell A., Romig H., Grim M. G., Lincoln S., Hardy J., Yu X., Picciano M., Fechteler K., Citron M., Kopan R., Pesold B., Keck S., Baader M., Tomita T., Lwatsubo T., Baumeister R. & Haass C. (1999) A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J. Biol. Chem. 274, 2866928673.
  • Struffi G. & Greenwald I. (1999) Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398, 522525.
  • Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos L. Jr, Eckman C., Golde T. E. & Younkin S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 13361340.
  • Vassar R., Bennett B. D., Babu-Khan S., Kahn S., Mendiaz E. A., Denis P., Teplow D. B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M. A., Biere A. L., Curran E., Burgess T., Louis J. C., Collins F., Treanor J., Rogers G. & Citron M. (1999) beta-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE. Science 286, 735741.DOI: 10.1126/science.286.5440.735
  • Watts G. F. & Burke V. (1996) Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr. Opin. Lipid. 7, 341355.
  • Wisniewski H. M. & Silverman W. (1997) Diagnostic criteria for the neuropathological assessment of Alzheimer's disease: current status and major issues. Neurobiol. Aging 18, S43S50.DOI: 10.1016/s0197-4580(97)00068-7
  • Wolfe M. S., Citron M., Diehl T. S., Xia W., Donkor I. O. & Selkoe D. J. (1998) A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity. J. Med. Chem. 41, 69.
  • Yamazaki T. & Ihara Y. (1998) Effects of specific protease inhibitors on amyloid beta-protein 42 secretion. Neurobiol. Aging 19, S77S79.DOI: 10.1016/s0197-4580(98)00031-1
  • Yan R., Bienkowski M. J., Shuck M. E., Miao H., Tory M. C., Pauley A. M., Brashier J. R., Stratman N. C., Mathews W. R., Buhl A. E., Carter D. B., Tomasselli A. G., Parodi L. A., Heinrikson R. L. & Gurney M. E. (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402, 533537.